Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
VIENNA, Sept. 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales, Corporate and Business Development, and Alliance Management. Staph will also play a key role with the other Management Board members in helping drive forward the Company's strategy. Prior to the appointment to Intercell AG's Management Board, Staph had stepped down from his position as member of the Supervisory Board of the company.
"Staph has an outstanding track record in the vaccines industry and has made major contributions to the success of some key vaccines businesses globally. His commercial and strategic experience ideally complement the skills of our current Management Board," said Gerd Zettlmeissl, Chief Executive Officer of Intercell AG. "We are proud to have Staph working with us towards the next growth phase of our Company."
"Having been a member of Intercell's Supervisory Board for almost five years, I have been impressed with the progress and capabilities of the Company and its people in creating value through innovation, industrialization and commercialization," said Staph Bakali. "I am delighted to join a very dynamic team and look forward to helping develop the business further."
Staph brings 20 years of vaccine industry experience from his previous leadership positions. He was recently Chief Executive Officer of Genocea Biosciences, a Boston (U.S.) based innovative biotech vaccine company, and previously Chief Operating Officer for ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK), which were acquired by GlaxoSmithKline and Chiron, respectively. Staph Bakali was also previously head of Sales and Marketing for Chiron's global vaccine business and SmithKline Beecham's Vaccine Business Unit in France. Staph holds a Masters d